In this issue:
Polatuzumab vedotin in previously untreated DLBCL
Axicabtagene ciloleucel in R/R indolent NHL
Romidepsin + CHOP in previously untreated PTCL
Ibrutinib + rituximab for older patients with MCL
Venetoclax discontinuation/dose modification in R/R CML
TP53 genomic alterations in LBCL treated with CAR T-cell
DLBCL in patients >65 years: 3-year real-world data
Extramedullary disease relapse/progression after blinatumomab for ALL
Venetoclax + azacitidine and donor lymphocyte infusion in relapsed AML
PD-1 inhibitor + GVD for R/R Hodgkin lymphoma
Please login below to download this issue (PDF)